CompletedPhase 3

Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).

Russia20 participantsStarted 2021-03-01

Plain-language summary

This is a pilot randomized controlled trial aimed to evaluate the effect of teriparatide on the clinical course of hypocalcemia after parathyroidectomy for secondary hyperparathyroidism in dialysis-dependent patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age \> 18 years;
✓. Patients with end-stage renal disease (ESRD) receiving hemodialysis or peritoneal dialysis treatment \> 3 months prior surgery;
✓. Severe secondary hyperparathyroidism defined as iPTH level \> 800 pg/ml, followed with hypercalcemia and/or hyperphosphatemia; with presence of one or more nodular or diffuse parathyroid hyperplasia confirmed with CT;
✓. Performed total parathyroidectomy with autotransplantation of the parathyroid tissue.

Exclusion criteria

✕. Emergency surgery;
✕. Primary hyperparathyroidism as a cause of ESRD;
✕. Scheduled (before surgery) blood transfusion;
✕. Re-operative surgery;
✕. Known allergy to the study drug.
✕. Malignant neoplasms of bone tissue (primary or metastatic).

What they're measuring

Total serum calcium level

Timeframe: Day 1,2,3,4,5

Trial details

NCT IDNCT04750460

SponsorSaint Petersburg State University, Russia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-02-16

View on ClinicalTrials.gov More Secondary Hyperparathyroidism trials